BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Bajaj JS, Khoruts A. Microbiota changes and intestinal microbiota transplantation in liver diseases and cirrhosis. Journal of Hepatology 2020;72:1003-27. [DOI: 10.1016/j.jhep.2020.01.017] [Cited by in Crossref: 34] [Cited by in F6Publishing: 37] [Article Influence: 17.0] [Reference Citation Analysis]
Number Citing Articles
1 Shen YC, Hsu HC, Lin TM, Chang YS, Hu LF, Chen LF, Lin SH, Kuo PI, Chen WS, Lin YC, Chen JH, Liang YC, Chang CC. H1-Antihistamines Reduce the Risk of Hepatocellular Carcinoma in Patients With Hepatitis B Virus, Hepatitis C Virus, or Dual Hepatitis B Virus-Hepatitis C Virus Infection. J Clin Oncol 2022;:JCO2101802. [PMID: 35044851 DOI: 10.1200/JCO.21.01802] [Reference Citation Analysis]
2 Bajaj JS, Sikaroodi M, Shamsaddini A, Henseler Z, Santiago-Rodriguez T, Acharya C, Fagan A, Hylemon PB, Fuchs M, Gavis E, Ward T, Knights D, Gillevet PM. Interaction of bacterial metagenome and virome in patients with cirrhosis and hepatic encephalopathy. Gut 2021;70:1162-73. [PMID: 32998876 DOI: 10.1136/gutjnl-2020-322470] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 5.0] [Reference Citation Analysis]
3 Lin SH, Chang YS, Lin TM, Hu LF, Hou TY, Hsu HC, Shen YC, Kuo PI, Chen WS, Lin YC, Chen JH, Chang CC. Proton Pump Inhibitors Increase the Risk of Autoimmune Diseases: A Nationwide Cohort Study. Front Immunol 2021;12:736036. [PMID: 34659225 DOI: 10.3389/fimmu.2021.736036] [Reference Citation Analysis]
4 Cañamares-Orbis P, Bernal-Monterde V, Sierra-Gabarda O, Casas-Deza D, Garcia-Rayado G, Cortes L, Lué A. Impact of Liver and Pancreas Diseases on Nutritional Status. Nutrients 2021;13:1650. [PMID: 34068295 DOI: 10.3390/nu13051650] [Reference Citation Analysis]
5 Reuter B, Bajaj JS. Microbiome: Emerging Concepts in Patients with Chronic Liver Disease.Clin Liver Dis. 2020;24:493-520. [PMID: 32620285 DOI: 10.1016/j.cld.2020.04.006] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
6 Acharya C, Bajaj JS. Chronic Liver Diseases and the Microbiome-Translating Our Knowledge of Gut Microbiota to Management of Chronic Liver Disease. Gastroenterology 2021;160:556-72. [PMID: 33253686 DOI: 10.1053/j.gastro.2020.10.056] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 3.5] [Reference Citation Analysis]
7 Xiong Y, Wu L, Shao L, Wang Y, Huang Z, Huang X, Li C, Wu A, Liu Z, Fan X, Zhou P. Dynamic Alterations of the Gut Microbial Pyrimidine and Purine Metabolism in the Development of Liver Cirrhosis. Front Mol Biosci 2022;8:811399. [DOI: 10.3389/fmolb.2021.811399] [Reference Citation Analysis]
8 Chen B, Huang H, Pan CQ. The role of gut microbiota in hepatitis B disease progression and treatment. J Viral Hepat 2021. [PMID: 34415656 DOI: 10.1111/jvh.13595] [Reference Citation Analysis]
9 Xu HM, Huang HL, Zhou YL, Zhao HL, Xu J, Shou DW, Liu YD, Zhou YJ, Nie YQ. Fecal Microbiota Transplantation: A New Therapeutic Attempt from the Gut to the Brain. Gastroenterol Res Pract 2021;2021:6699268. [PMID: 33510784 DOI: 10.1155/2021/6699268] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
10 Liu J, Yang D, Wang X, Asare PT, Zhang Q, Na L, Shao L. Gut Microbiota Targeted Approach in the Management of Chronic Liver Diseases. Front Cell Infect Microbiol 2022;12:774335. [DOI: 10.3389/fcimb.2022.774335] [Reference Citation Analysis]
11 Fernandez-Cantos MV, Garcia-Morena D, Iannone V, El-Nezami H, Kolehmainen M, Kuipers OP. Role of microbiota and related metabolites in gastrointestinal tract barrier function in NAFLD. Tissue Barriers 2021;:1879719. [PMID: 34280073 DOI: 10.1080/21688370.2021.1879719] [Reference Citation Analysis]
12 Ancona G, Alagna L, Lombardi A, Palomba E, Castelli V, Renisi G, Dondossola D, Iavarone M, Muscatello A, Gori A, Bandera A. The Interplay between Gut Microbiota and the Immune System in Liver Transplant Recipients and Its Role in Infections. Infect Immun 2021;89:e0037621. [PMID: 34460287 DOI: 10.1128/IAI.00376-21] [Reference Citation Analysis]
13 Yu X, Jin Y, Zhou W, Xiao T, Wu Z, Su J, Gao H, Shen P, Zheng B, Luo Q, Li L, Xiao Y. Rifaximin Modulates the Gut Microbiota to Prevent Hepatic Encephalopathy in Liver Cirrhosis Without Impacting the Resistome. Front Cell Infect Microbiol 2022;11:761192. [DOI: 10.3389/fcimb.2021.761192] [Reference Citation Analysis]
14 Bruneau A, Hundertmark J, Guillot A, Tacke F. Molecular and Cellular Mediators of the Gut-Liver Axis in the Progression of Liver Diseases. Front Med (Lausanne) 2021;8:725390. [PMID: 34650994 DOI: 10.3389/fmed.2021.725390] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
15 Liu C, Wang YL, Yang YY, Zhang NP, Niu C, Shen XZ, Wu J. Novel approaches to intervene gut microbiota in the treatment of chronic liver diseases. FASEB J 2021;35:e21871. [PMID: 34473374 DOI: 10.1096/fj.202100939R] [Reference Citation Analysis]
16 Bloom PP, Donlan J, Torres Soto M, Daidone M, Hohmann E, Chung RT. Fecal microbiota transplant improves cognition in hepatic encephalopathy and its effect varies by donor and recipient. Hepatol Commun 2022. [PMID: 35384391 DOI: 10.1002/hep4.1950] [Reference Citation Analysis]
17 Guixé-muntet S, Zhu C, Xie W, Gracia-sancho J. Novel therapeutics for portal hypertension and fibrosis in chronic liver disease. Pharmacology & Therapeutics 2020;215:107626. [DOI: 10.1016/j.pharmthera.2020.107626] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
18 Solé C, Ginès P. Reply. Gastroenterology 2021;160:2206. [PMID: 33484681 DOI: 10.1053/j.gastro.2021.01.204] [Reference Citation Analysis]
19 Madsen M, Kimer N, Bendtsen F, Petersen AM. Fecal microbiota transplantation in hepatic encephalopathy: a systematic review. Scand J Gastroenterol 2021;56:560-9. [PMID: 33840331 DOI: 10.1080/00365521.2021.1899277] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
20 Floreani A, De Martin S, Ikeura T, Okazaki K, Gershwin ME. Gut microbial profiling as a therapeutic and diagnostic target for managing primary biliary cholangitis. Expert Opinion on Orphan Drugs 2020;8:507-14. [DOI: 10.1080/21678707.2020.1865917] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
21 Gupta H, Min B, Ganesan R, Gebru YA, Sharma SP, Park E, Won S, Jeong J, Lee S, Cha M, Kwon G, Jeong M, Hyun J, Eom J, Park H, Yoon S, Choi M, Kim D, Suk K. Gut Microbiome in Non-Alcoholic Fatty Liver Disease: From Mechanisms to Therapeutic Role. Biomedicines 2022;10:550. [DOI: 10.3390/biomedicines10030550] [Reference Citation Analysis]
22 Xiao Y, Wu D, Shi X, Liu S, Hu X, Zhou C, Tian X, Liu H, Long H, Li Z, Wang J, Tan T, Xu Y, Chen B, Liu T, Zhang H, Zheng S, Hu S, Song J, Tang J, Song J, Cheng Z, Xu W, Shen Y, Yu W, Xu Y, Li J, Zhou J, Wang F, Chen M. High Child-Pugh and CRUB65 scores predict mortality of decompensated cirrhosis patients with COVID-19: A 23-center, retrospective study. Virulence 2021;12:1199-208. [PMID: 33870852 DOI: 10.1080/21505594.2021.1909894] [Reference Citation Analysis]
23 Huang HC, Tsai MH, Chang CC, Pun CK, Huang YH, Hou MC, Lee FY, Hsu SJ. Microbiota transplants from feces or gut content attenuated portal hypertension and portosystemic collaterals in cirrhotic rats. Clin Sci (Lond) 2021;135:2709-28. [PMID: 34870313 DOI: 10.1042/CS20210602] [Reference Citation Analysis]
24 Iwakiri Y, Trebicka J. Portal hypertension in cirrhosis: Pathophysiological mechanisms and therapy. JHEP Rep 2021;3:100316. [PMID: 34337369 DOI: 10.1016/j.jhepr.2021.100316] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
25 Ding JH, Jin Z, Yang XX, Lou J, Shan WX, Hu YX, Du Q, Liao QS, Xie R, Xu JY. Role of gut microbiota via the gut-liver-brain axis in digestive diseases. World J Gastroenterol 2020; 26(40): 6141-6162 [PMID: 33177790 DOI: 10.3748/wjg.v26.i40.6141] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
26 Gupta H, Suk KT, Kim DJ. Gut Microbiota at the Intersection of Alcohol, Brain, and the Liver. J Clin Med 2021;10:541. [PMID: 33540624 DOI: 10.3390/jcm10030541] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
27 Li B, Yang C, Qian Z, Huang Y, Wang X, Zhong G, Chen J. Spontaneous Fungal Ascites Infection in Patients with Cirrhosis: An Analysis of 10 Cases. Infect Dis Ther 2021;10:1033-43. [PMID: 33709385 DOI: 10.1007/s40121-021-00422-w] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
28 Yang L, Li Y, Wang S, Bian X, Jiang X, Wu J, Wang K, Wang Q, Xia J, Jiang S, Zhuge A, Yuan Y, Li S, Li L. Western Diet Aggravated Carbon Tetrachloride-Induced Chronic Liver Injury by Disturbing Gut Microbiota and Bile Acid Metabolism. Mol Nutr Food Res 2021;65:e2000811. [PMID: 33458949 DOI: 10.1002/mnfr.202000811] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
29 Wang R, Tang R, Li B, Ma X, Schnabl B, Tilg H. Gut microbiome, liver immunology, and liver diseases.Cell Mol Immunol. 2021;18:4-17. [PMID: 33318628 DOI: 10.1038/s41423-020-00592-6] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 8.0] [Reference Citation Analysis]
30 Liang Q, Zhang M, Hu Y, Zhang W, Zhu P, Chen Y, Xue P, Li Q, Wang K. Gut Microbiome Contributes to Liver Fibrosis Impact on T Cell Receptor Immune Repertoire. Front Microbiol 2020;11:571847. [PMID: 33329430 DOI: 10.3389/fmicb.2020.571847] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
31 Caraceni P, Vargas V, Solà E, Alessandria C, de Wit K, Trebicka J, Angeli P, Mookerjee RP, Durand F, Pose E, Krag A, Bajaj JS, Beuers U, Ginès P; Liverhope Consortium. The Use of Rifaximin in Patients With Cirrhosis. Hepatology 2021. [PMID: 33421158 DOI: 10.1002/hep.31708] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 6.0] [Reference Citation Analysis]
32 Zhang P, Zheng L, Duan Y, Gao Y, Gao H, Mao D, Luo Y. Gut microbiota exaggerates triclosan-induced liver injury via gut-liver axis. J Hazard Mater 2021;421:126707. [PMID: 34315018 DOI: 10.1016/j.jhazmat.2021.126707] [Reference Citation Analysis]
33 Li W, Chen X, Li M, Cai Z, Gong H, Yan M. Microplastics as an aquatic pollutant affect gut microbiota within aquatic animals. J Hazard Mater 2021;423:127094. [PMID: 34530278 DOI: 10.1016/j.jhazmat.2021.127094] [Reference Citation Analysis]
34 Chopyk DM, Grakoui A. Contribution of the Intestinal Microbiome and Gut Barrier to Hepatic Disorders. Gastroenterology 2020;159:849-63. [PMID: 32569766 DOI: 10.1053/j.gastro.2020.04.077] [Cited by in Crossref: 22] [Cited by in F6Publishing: 26] [Article Influence: 11.0] [Reference Citation Analysis]
35 Zheng Z, Wang B. The Gut-Liver Axis in Health and Disease: The Role of Gut Microbiota-Derived Signals in Liver Injury and Regeneration. Front Immunol 2021;12:775526. [PMID: 34956204 DOI: 10.3389/fimmu.2021.775526] [Reference Citation Analysis]
36 Liang Y, Cui L, Gao J, Zhu M, Zhang Y, Zhang HL. Gut Microbial Metabolites in Parkinson's Disease: Implications of Mitochondrial Dysfunction in the Pathogenesis and Treatment. Mol Neurobiol 2021;58:3745-58. [PMID: 33825149 DOI: 10.1007/s12035-021-02375-0] [Reference Citation Analysis]
37 Trebicka J, Macnaughtan J, Schnabl B, Shawcross DL, Bajaj JS. The microbiota in cirrhosis and its role in hepatic decompensation. J Hepatol 2021;75 Suppl 1:S67-81. [PMID: 34039493 DOI: 10.1016/j.jhep.2020.11.013] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
38 Kronsten VT, Shawcross DL. Hepatic encephalopathy and depression in chronic liver disease: is the common link systemic inflammation? Anal Biochem 2021;:114437. [PMID: 34715068 DOI: 10.1016/j.ab.2021.114437] [Reference Citation Analysis]
39 Zhang T, Zhu G, Lu B, Qian Z, Peng Q. Protein corona formed in the gastrointestinal tract and its impacts on oral delivery of nanoparticles. Med Res Rev 2021;41:1835-50. [DOI: 10.1002/med.21767] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
40 Acharya C, Bajaj JS. Hepatic Encephalopathy and Liver Transplantation: The Past, Present, and Future Toward Equitable Access. Liver Transpl 2021. [PMID: 34018659 DOI: 10.1002/lt.26099] [Reference Citation Analysis]
41 Philips CA, Ahamed R, Rajesh S, Augustine P. 'You know my name, but not my story' - Deciding on an accurate nomenclature for faecal microbiota transplantation. J Hepatol. 2020;72:1212-1213. [PMID: 32197801 DOI: 10.1016/j.jhep.2020.02.004] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
42 Bajaj JS, Reddy KR, O'Leary JG, Vargas HE, Lai JC, Kamath PS, Tandon P, Wong F, Subramanian RM, Thuluvath P, Fagan A, White MB, Gavis EA, Sehrawat T, de la Rosa Rodriguez R, Thacker LR, Sikaroodi M, Garcia-Tsao G, Gillevet PM. Serum Levels of Metabolites Produced by Intestinal Microbes and Lipid Moieties Independently Associated With Acute-on-Chronic Liver Failure and Death in Patients With Cirrhosis. Gastroenterology 2020;159:1715-1730.e12. [PMID: 32687928 DOI: 10.1053/j.gastro.2020.07.019] [Cited by in Crossref: 15] [Cited by in F6Publishing: 11] [Article Influence: 7.5] [Reference Citation Analysis]
43 Saboo K, Shamsaddini A, Iyer MV, Hu C, Fagan A, Gavis EA, White MB, Fuchs M, Heuman DM, Sikaroodi M, Iyer RK, Gillevet PM, Bajaj JS. Sex is associated with differences in gut microbial composition and function in hepatic encephalopathy. J Hepatol 2021;74:80-8. [PMID: 32679299 DOI: 10.1016/j.jhep.2020.06.046] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
44 Pelle J, Castelli FA, Rudler M, Alioua I, Colsch B, Fenaille F, Junot C, Thabut D, Weiss N. Metabolomics in the understanding and management of hepatic encephalopathy. Anal Biochem 2022;636:114477. [PMID: 34808106 DOI: 10.1016/j.ab.2021.114477] [Reference Citation Analysis]
45 Wang C, Yuan Z, Sun Y, Yao X, Li R, Li S. Effect of Chronic Exposure to Textile Wastewater Treatment Plant Effluents on Growth Performance, Oxidative Stress, and Intestinal Microbiota in Adult Zebrafish (Danio rerio). Front Microbiol 2021;12:782611. [PMID: 34899664 DOI: 10.3389/fmicb.2021.782611] [Reference Citation Analysis]
46 Piano S, Angeli P. Bacterial Infections in Cirrhosis as a Cause or Consequence of Decompensation? Clin Liver Dis 2021;25:357-72. [PMID: 33838855 DOI: 10.1016/j.cld.2021.01.006] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
47 Mitten EK, Baffy G. Microbiota transplantation in portal hypertension: promises and pitfalls. Clin Sci (Lond) 2022;136:425-9. [PMID: 35333331 DOI: 10.1042/CS20220029] [Reference Citation Analysis]
48 Mandorfer M, Simbrunner B. Prevention of First Decompensation in Advanced Chronic Liver Disease. Clin Liver Dis 2021;25:291-310. [PMID: 33838851 DOI: 10.1016/j.cld.2021.01.003] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
49 Sivaraj S, Copeland JK, Malik A, Pasini E, Angeli M, Azhie A, Husain S, Kumar D, Allard J, Guttman DS, Humar A, Bhat M. Characterization and predictive functional profiles on metagenomic 16S rRNA data of liver transplant recipients: A longitudinal study. Clin Transplant 2021;:e14534. [PMID: 34781411 DOI: 10.1111/ctr.14534] [Reference Citation Analysis]
50 Bajaj JS, Shamsaddini A, Acharya C, Fagan A, Sikaroodi M, Gavis E, McGeorge S, Khoruts A, Fuchs M, Sterling RK, Lee H, Gillevet PM. Multiple bacterial virulence factors focused on adherence and biofilm formation associate with outcomes in cirrhosis. Gut Microbes 2021;13:1993584. [PMID: 34743650 DOI: 10.1080/19490976.2021.1993584] [Reference Citation Analysis]
51 Mandato C, Delli Bovi AP, Vajro P. The gut-liver axis as a target of liver disease management. Hepatobiliary Surg Nutr 2021;10:100-2. [PMID: 33575294 DOI: 10.21037/hbsn.2020.03.27] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]